Although lapatinib was beneficial in HER2 IHC 3+ patients and in some Asian and younger patients, these trials did not meet the primary endpoint; thus, lapatinib is not recommended for patients with HER2-positive advanced GC, and its use may require a more rigorous screening strategy. The gene discussed is ERBB2; the disease is gastric cancer.